Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma
Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma
复制标题
DOI：
10.2169/internalmedicine.55.6140
复制
发表时间：
2016-01-01
影响因子：
1.2
通讯作者：
Kimura, Shinya
中科院分区：
文献类型：
--
作者：
Ureshino, Hiroshi;Nishioka, Atsujiro;Kimura, Shinya
利妥昔单抗诱导的急性血小板减少症（RIAT）是利妥昔单抗给药的罕见并发症，尚未在滤泡性淋巴瘤（FL）中描述。一名65岁男性接受利妥昔单抗治疗高肿瘤负荷滤泡性淋巴瘤的白血病期。第二天，他的血小板计数突然从85，000/μ L下降到5，000/μ L，几天后在没有特殊治疗的情况下自发恢复。我们推测利妥昔单抗敏感的高肿瘤负荷FL中输注相关细胞因子释放综合征的发生促成了RIAT的发展。对于RIAT高危患者，建议经常监测血小板计数。
Rituximab-induced acute thrombocytopenia (RIAT), a rare complication of rituximab administration, has not yet been described in follicular lymphoma (FL). A 65-year-old man received rituximab for the treatment of high tumor burden follicular lymphoma in the leukemic phase. The next day, his platelet count abruptly dropped from 85,000 to 5,000/mu L, which spontaneously recovered in a few days without specific treatment. We speculate that the occurrence of infusion-related cytokine release syndrome in rituximab-sensitive high tumor burden FL contributed to the development of RIAT. Frequent monitoring of the platelet count is advisable for select patients considered to be at a high risk for RIAT.